ALNY
Alnylam Pharmaceuticals, Inc. NASDAQ Listed Jun 1, 2004$276.67
-2.14%
vs $282.72
Mkt Cap $36.9B
52w Low $273.11
1.6% of range
52w High $495.55
50d MA $301.53
200d MA $375.24
P/E (TTM)
121.3x
EV/EBITDA
64.9x
P/B
45.9x
Debt/Equity
1.6x
ROE
39.8%
P/FCF
80.1x
RSI (14)
36.00
ATR (14)
$10.17
Beta
0.38
50d MA
$301.53
200d MA
$375.24
Avg Volume
1.1M
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
675 West Kendall Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 0.90 | 1.51 | +68.7% | 301.19 | +2.1% | +2.8% | -4.3% | +0.6% | +1.1% | +0.6% | — |
| Feb 12, 2026 | BMO | 1.16 | 0.82 | -29.3% | 322.28 | -2.4% | -4.3% | +1.9% | +5.8% | +0.0% | +2.0% | — |
| Oct 30, 2025 | BMO | 0.56 | 2.90 | +416.9% | 481.59 | -6.6% | -6.7% | +1.4% | -4.8% | -2.4% | +2.6% | — |
| Jul 31, 2025 | BMO | -0.54 | 0.32 | +158.9% | 339.80 | +3.0% | +15.4% | +2.4% | +4.4% | -0.2% | +2.2% | — |
| May 1, 2025 | BMO | -0.89 | -0.01 | +98.9% | 263.24 | -2.3% | -3.1% | +1.7% | +5.5% | -1.4% | +2.5% | — |
| Feb 13, 2025 | BMO | -0.62 | 0.06 | +109.7% | 265.96 | -2.8% | -0.4% | -3.2% | -2.5% | +0.2% | +0.2% | — |
| Oct 31, 2024 | BMO | -0.92 | -0.50 | +45.4% | 281.49 | -2.2% | -5.3% | +2.7% | -1.4% | -1.7% | +2.9% | — |
| Aug 1, 2024 | BMO | -1.07 | 0.56 | +152.3% | 237.46 | +5.3% | +13.1% | +1.3% | -2.6% | -0.9% | -0.9% | — |
| May 2, 2024 | BMO | -1.12 | -0.16 | +85.7% | 149.96 | +0.6% | +0.2% | +1.3% | -0.7% | +2.1% | -1.3% | — |
| Feb 15, 2024 | BMO | -1.20 | -1.10 | +8.3% | 164.15 | -8.6% | -10.2% | -0.3% | +1.8% | +3.4% | +5.2% | — |
| Nov 2, 2023 | BMO | -1.34 | 1.15 | +185.8% | 157.00 | +3.4% | +2.9% | +3.6% | -0.1% | +1.8% | -0.5% | — |
| Aug 3, 2023 | BMO | -1.72 | -2.21 | -28.5% | 187.01 | -2.6% | +1.7% | -2.4% | -0.7% | +0.3% | +0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Citigroup | Initiates | Buy | $380 | $286.27 | $289.00 | +1.0% | +2.8% | +1.4% | +0.7% | -1.0% | -0.7% |
| May 1 | RBC Capital | Maintains | Outperform → Outperform | — | $309.49 | $308.76 | -0.2% | -4.3% | +0.6% | +1.1% | +0.6% | -2.3% |
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $309.49 | $308.76 | -0.2% | -4.3% | +0.6% | +1.1% | +0.6% | -2.3% |
| Apr 13 | Truist | Maintains | Buy → Buy | — | $322.11 | $320.66 | -0.5% | +3.4% | +1.9% | -1.8% | -4.0% | -3.3% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $308.05 | $313.34 | +1.7% | +6.7% | -0.2% | -3.3% | -0.4% | +4.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $308.05 | $313.34 | +1.7% | +6.7% | -0.2% | -3.3% | -0.4% | +4.7% |
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $313.41 | $311.22 | -0.7% | +1.8% | +0.5% | -1.8% | -1.2% | +0.3% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $332.61 | $328.86 | -1.1% | +0.0% | +2.0% | -0.9% | -2.0% | +1.1% |
| Feb 17 | Freedom Broker | Upgrade | Hold → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +0.0% | +2.0% | -0.9% | -2.0% |
| Feb 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +0.0% | +2.0% | -0.9% | -2.0% |
| Feb 17 | Freedom Capital Markets | Upgrade | Hold → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +0.0% | +2.0% | -0.9% | -2.0% |
| Feb 13 | Chardan Capital | Maintains | Buy → Buy | — | $308.48 | $302.55 | -1.9% | +1.9% | +5.8% | +0.0% | +2.0% | -0.9% |
| Feb 12 | Needham | Maintains | Buy → Buy | — | $322.28 | $314.42 | -2.4% | -4.3% | +1.9% | +5.8% | +0.0% | +2.0% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $346.79 | $343.10 | -1.1% | -2.5% | +0.3% | +3.7% | +0.0% | -5.9% |
| Jan 30 | BofA Securities | Maintains | Buy → Buy | — | $346.79 | $343.10 | -1.1% | -2.5% | +0.3% | +3.7% | +0.0% | -5.9% |
| Jan 30 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $346.79 | $343.10 | -1.1% | -2.5% | +0.3% | +3.7% | +0.0% | -5.9% |
| Jan 20 | RBC Capital | Maintains | Outperform → Outperform | — | $359.27 | $350.70 | -2.4% | -1.0% | +2.8% | +1.2% | -3.2% | +0.9% |
| Jan 20 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $359.27 | $350.70 | -2.4% | -1.0% | +2.8% | +1.2% | -3.2% | +0.9% |
| Jan 12 | BofA Securities | Maintains | Buy → Buy | — | $398.29 | $377.82 | -5.1% | -6.9% | -0.3% | -0.8% | -2.1% | +0.0% |
| Jan 12 | Needham | Maintains | Buy → Buy | — | $398.29 | $377.82 | -5.1% | -6.9% | -0.3% | -0.8% | -2.1% | +0.0% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $422.50 | $420.18 | -0.5% | -5.5% | -0.3% | -6.9% | -0.3% | -0.8% |
| Dec 15 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $397.55 | $394.22 | -0.8% | -1.5% | -0.1% | +0.2% | +1.0% | +1.1% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $404.46 | $403.36 | -0.3% | +2.0% | -3.7% | -1.5% | -0.1% | +0.2% |
| Nov 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $441.70 | $443.53 | +0.4% | +2.3% | +0.2% | +0.3% | -1.1% | +2.5% |
| Nov 5 | Freedom Broker | Maintains | Buy → Buy | — | $423.47 | $422.11 | -0.3% | +2.6% | +1.4% | +0.5% | -0.2% | +2.3% |
| Oct 31 | Barclays | Maintains | Overweight → Overweight | — | $449.56 | $449.00 | -0.1% | +1.4% | -4.8% | -2.4% | +2.6% | +1.4% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $449.56 | $449.00 | -0.1% | +1.4% | -4.8% | -2.4% | +2.6% | +1.4% |
| Oct 30 | Jefferies | Maintains | Buy → Buy | — | $481.59 | $450.00 | -6.6% | -6.7% | +1.4% | -4.8% | -2.4% | +2.6% |
| Oct 17 | Truist | Maintains | Buy → Buy | — | $481.07 | $481.65 | +0.1% | +0.1% | +2.0% | -3.5% | -1.9% | -0.2% |
| Oct 13 | JP Morgan | Maintains | Overweight → Overweight | — | $460.46 | $456.13 | -0.9% | +1.0% | +0.9% | +0.2% | +2.3% | +0.1% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $456.95 | $460.28 | +0.7% | +0.8% | +1.0% | +0.9% | +0.2% | +2.3% |
| Oct 6 | Stifel | Maintains | Buy → Buy | — | $456.35 | $458.69 | +0.5% | -1.0% | +1.7% | -1.9% | +1.4% | +0.8% |
| Oct 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $456.35 | $458.69 | +0.5% | -1.0% | +1.7% | -1.9% | +1.4% | +0.8% |
| Sep 19 | RBC Capital | Maintains | Outperform → Outperform | — | $452.17 | $457.68 | +1.2% | +0.3% | +1.2% | -1.0% | +0.9% | -1.9% |
| Sep 17 | BofA Securities | Maintains | Buy → Buy | — | $461.24 | $455.76 | -1.2% | -2.1% | +0.1% | +0.3% | +1.2% | -1.0% |
| Sep 16 | Goldman Sachs | Maintains | Buy → Buy | — | $461.14 | $465.14 | +0.9% | +0.0% | -2.1% | +0.1% | +0.3% | +1.2% |
| Sep 15 | Jefferies | Maintains | Buy → Buy | — | $465.89 | $464.80 | -0.2% | -1.0% | +0.0% | -2.1% | +0.1% | +0.3% |
| Sep 11 | Evercore ISI | Maintains | Outperform → Outperform | — | $469.31 | $474.34 | +1.1% | -0.2% | -0.6% | -1.0% | +0.0% | -2.1% |
| Sep 8 | BMO Capital | Maintains | Outperform → Outperform | — | $452.00 | $457.31 | +1.2% | +0.7% | +6.0% | -2.7% | -0.2% | -0.6% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $446.51 | $445.84 | -0.2% | +0.1% | +0.1% | +1.4% | -0.3% | +0.7% |
| Sep 2 | Citigroup | Maintains | Buy → Buy | — | $446.51 | $445.84 | -0.2% | +0.1% | +0.1% | +1.4% | -0.3% | +0.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $428.14 | $429.33 | +0.3% | +1.6% | +0.9% | -0.9% | -1.2% | +0.6% |
| Aug 6 | JP Morgan | Maintains | Overweight → Overweight | — | $418.91 | $418.76 | -0.0% | +2.2% | +1.6% | +0.9% | -0.9% | -1.2% |
| Aug 4 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $401.80 | $406.65 | +1.2% | +4.4% | -0.2% | +2.2% | +1.6% | +0.9% |
| Aug 4 | Oppenheimer | Upgrade | Perform → Outperform | — | $401.80 | $406.65 | +1.2% | +4.4% | -0.2% | +2.2% | +1.6% | +0.9% |
| Aug 1 | Chardan Capital | Maintains | Buy → Buy | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | UBS | Maintains | Buy → Buy | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | Barclays | Maintains | Overweight → Overweight | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | PYOTT DAVID E IDir | — | Sell | 17 | $302.65 | $5K | 1,582 | +3.78% | -2.17% |
| Jun 1, 2026 | PYOTT DAVID E IDir | — | Sell | 495 | $300.72 | $149K | 1,599 | +3.78% | -2.17% |
| Jun 1, 2026 | PYOTT DAVID E IDir | — | Sell | 1,222 | $299.87 | $366K | 2,094 | +3.78% | -2.17% |
| Jun 1, 2026 | PYOTT DAVID E IDir | — | Sell | 1,175 | $298.91 | $351K | 3,316 | +3.78% | -2.17% |
| Jun 1, 2026 | PYOTT DAVID E IDir | — | Sell | 921 | $297.71 | $274K | 4,491 | +3.78% | -2.17% |
8-K · 5.02
!!! Very High
Alnylam Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Alnylam Pharmaceuticals appoints Benjamin F. Cravatt to its board as a Class III director, strengthening governance with an experienced addition to leadership.
May 27
8-K
Alnylam Pharmaceuticals, Inc. -- 8-K Filing
Alnylam surpassed $1 billion in quarterly product revenues for the first time, driven by AMVUTTRA's launch for ATTR-CM, signaling strong commercial momentum for the RNAi therapeutics leader.
Apr 30
8-K
Unknown — 8-K Filing
Tenaya Therapeutics (TNYA) is advancing its cardiac disease pipeline with positive momentum, suggesting potential near-term clinical catalysts that could justify its clinical-stage valuation if development programs succeed.
Mar 11
8-K · 1.01
!! High
Tenaya Therapeutics, Inc. -- 8-K 1.01: Collaboration Agreement
Tenaya Therapeutics secured a $10 million collaboration agreement with Alnylam Pharmaceuticals to develop RNA-based therapeutics, providing funding and potential revenue expansion for the smaller biotech firm.
Mar 5
8-K · 5.02
!!! Very High
Alnylam Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Alnylam's board granted a special equity award to new CEO Yvonne Greenstreet as part of her executive compensation package, effective March 2, 2026.
Mar 4
8-K
Alnylam Pharmaceuticals, Inc. -- 8-K Filing
Alnylam Pharmaceuticals advanced its RNAi pipeline with three new Phase 3 studies, four proprietary CTAs, and a novel manufacturing platform, positioning the company for sustained growth in genetic disease treatment.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 14,579,166 | $4.8B | Reduced | Mar 2026 |
| 2 | Capital World Investors | 10,802,348 | $3.6B | Reduced | Mar 2026 |
| 3 | Capital Research Global Investors | 9,471,181 | $3.1B | Added | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 6,491,280 | $2.1B | New | Mar 2026 |
| 5 | Jpmorgan Chase & Co | 6,323,752 | $2.0B | Added | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 5,946,706 | $2.0B | New | Mar 2026 |
| 7 | Morgan Stanley | 1,940,314 | $772M | Added | Dec 2025 |
| 8 | Two Sigma Investments, Lp | 1,992,577 | $659M | Added | Mar 2026 |
| 9 | Dodge & Cox | 1,929,253 | $638M | Reduced | Mar 2026 |
| 10 | Clearbridge Investments, Llc | 1,356,036 | $449M | Added | Mar 2026 |
| 11 | Orbis Allan Gray Ltd | 1,334,825 | $442M | Reduced | Mar 2026 |
| 12 | Invesco Ltd. | 1,291,726 | $427M | Reduced | Mar 2026 |
| 13 | Marshall Wace, Llp | 1,099,318 | $364M | Added | Mar 2026 |
| 14 | D.e. Shaw & Co | 1,059,062 | $350M | Added | Mar 2026 |
| 15 | Bank Of America Corp /de/ | 966,912 | $320M | Reduced | Mar 2026 |
| 16 | Aqr Capital Management Llc | 913,104 | $298M | Reduced | Mar 2026 |
| 17 | Northern Trust Corp | 858,120 | $284M | — | Mar 2026 |
| 18 | Qube Research & Technologies Ltd | 838,187 | $277M | Added | Mar 2026 |
| 19 | Royal Bank Of Canada | 791,515 | $262M | Added | Mar 2026 |
| 20 | Amundi | 747,544 | $247M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | JPMorgan Large Cap Growth Fund | 2,036,592 | $674M | Mar 2026 |
| 2 | Fidelity OTC Portfolio | 1,336,524 | $452M | Jan 2026 |
| 3 | VANGUARD HEALTH CARE FUND | 1,309,033 | $443M | Jan 2026 |
| 4 | Fidelity Growth Company Fund | 1,300,974 | $433M | Feb 2026 |
| 5 | Dodge & Cox Stock Fund | 1,233,200 | $408M | Mar 2026 |
| 6 | iShares Biotechnology ETF | 979,642 | $324M | Mar 2026 |
| 7 | New Economy Fund | 867,315 | $289M | Feb 2026 |
| 8 | iShares Russell Mid-Cap Growth ETF | 850,606 | $281M | Mar 2026 |
| 9 | Ultra Fund | 747,000 | $253M | Jan 2026 |
| 10 | JPMorgan Mid Cap Growth Fund | 700,981 | $232M | Mar 2026 |
| 11 | Fidelity Extended Market Index Fund | 691,763 | $230M | Feb 2026 |
| 12 | Fidelity Blue Chip Growth Fund | 578,056 | $195M | Jan 2026 |
| 13 | Strategic Advisers Fidelity U.S. Total Stock Fund | 569,120 | $189M | Feb 2026 |
| 14 | Capital Group Growth ETF | 557,684 | $186M | Feb 2026 |
| 15 | iShares Russell 1000 Growth ETF | 511,131 | $169M | Mar 2026 |
| 16 | Invesco American Franchise Fund | 504,640 | $168M | Feb 2026 |
| 17 | Invesco NASDAQ 100 ETF | 502,493 | $167M | Feb 2026 |
| 18 | Select Biotechnology Portfolio | 496,683 | $165M | Feb 2026 |
| 19 | Fidelity Advisor Growth Opportunities Fund | 490,835 | $163M | Feb 2026 |
| 20 | iShares Russell Mid-Cap ETF | 484,627 | $160M | Mar 2026 |
Valuation
Market Cap
$36.94B
Enterprise Value
$36.18B
P/E (TTM)
121.34x
Forward P/E
41.31x
PEG Ratio
-0.79x
P/B
45.93x
P/S
10.03x
P/FCF
80.07x
EV/EBITDA
64.92x
Shares Out
134.7M
Financials (TTM)
Revenue
$3.71B
Net Income
$313.7M
EBITDA
$557.2M
Free Cash Flow
$465.4M
Op Cash Flow
$524.1M
EPS Basic
$2.39
EPS Diluted
$2.33
EPS Forward
$6.70
Gross Margin
81.8%
Op Margin
13.5%
Net Margin
8.5%
Balance Sheet
Total Assets
$4.97B
Total Liab.
$4.18B
Total Equity
$789.2M
Cash
$2.91B
LT Debt
$1.01B
Book Value/Sh
$6.02
Debt/Equity
1.62x
Current Ratio
2.76
Quick Ratio
2.71
Returns & Growth
ROE
39.8%
ROA
6.3%
ROIC
13.7%
Rev Growth YoY
+65.2%
EPS Growth YoY
+209.6%
Price Returns
2W
+2.9%
1M
-2.4%
3M
-9.3%
6M
-33.1%
12M
-0.8%
Technicals
52W High
$495.55
52W Low
$273.11
50d MA
$301.53
200d MA
$375.24
RSI (14)
36.00
ATR (14)
$10.17
Beta
0.38
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$454.93
High
$530.00
Low
$351.00
Median
$458.00
Data updated apr 24, 2026 5:26pm
· Source: financialmodelingprep.com